Cited by 157Radiopharmaceutical Chemistry and ApplicationsRadioactivity and Radon MeasurementsChemical Reactions and Isotopes

The DOI matches its Crossref record; 266 of the 283 references it cites were found in a registry or an index.

Development of targeted alpha particle therapy for solid tumors.

Open access

Tafreshi, Narges K., Doligalski, Michael L., Tichacek, Christopher J., Pandya, Darpan N., Budzevich, Mikalai M., El-Haddad, Ghassan, Khushalani, Nikhil I., Moros, Eduardo G., McLaughlin, Mark L., Wadas, Thaddeus J., Morse, David L.·2019·Molecules

DOI 10.3390/molecules24234314PMC PMC6930656

Open this paper in CoChat — free account Open PDF

Abstract

Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or small molecules that recognize tumor-associated antigens or cell-surface receptors. Because of the high linear energy transfer (LET) and short range of alpha (α) particles in tissue, cancer cells can be significantly damaged while causing minimal toxicity to surrounding healthy cells. Recent clinical studies have demonstrated the remarkable efficacy of TAT in the treatment of metastatic, castration-resistant prostate cancer. In this comprehensive review, we discuss the current consensus regarding the properties of the α-particle-emitting radionuclides that are potentially relevant for use in the clinic; the TAT-mediated mechanisms responsible for cell death; the different classes of targeting moieties and radiometal chelators available for TAT development; current approaches to calculating radiation dosimetry for TATs; and lead optimization via medicinal chemistry to improve the TAT radiopharmaceutical properties. We have also summarized the use of TATs in pre-clinical and clinical studies to date.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.3390/molecules24234314

Cites

266 of 266 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Items 201–266 of 266

The potential for Cerenkov luminescence imaging of alpha-emitting radionuclides
Ackerman, N. L., & Graves, E. E. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/3/771 · Cited by 46
Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
Elgqvist, J., Bernhardt, P., Hultborn, R., Jensen, H. J., Karlsson, B., Lindegren, S., Warnhammar, E., & Jacobsson, L. (2005) · PubMed · Cited by 46
Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model
Nedrow, J. R., Josefsson, A., Park, S., Bäck, T. A., Hobbs, R. F., Brayton, C. F., Bruchertseifer, F., Morgenstern, A., & Sgouros, G. (2017) · EJNMMI Research · doi:10.1186/s13550-017-0303-2 · Cited by 45
Cerenkov Luminescence Imaging for Radiation Dose Calculation of a 90Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist
Lohrmann, C., Zhang, H., Thorek, D. L. J., Desai, P., ZANZONICO, P. B., O’Donoghue, J. A., Irwin, C. P., Reiner, T., Grimm, J., & Weber, W. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.149054 · Cited by 44
Targeted alpha anticancer therapies: update and future prospects
Allen, B., Huang, C., & Clarke, R. A. (2014) · Biologics · doi:10.2147/btt.s29947 · Cited by 44
Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate
Chan, H. S., Konijnenberg, M., de Blois, E., Koelewijn, S. J., Baum, R. P., Morgenstern, A., Bruchertseifer, F., Breeman, W. A. P., & de Jong, M. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0162-2 · Cited by 44
A Phase I Study of Samarium Lexidronam/Bortezomib Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
Berenson, J. R., Yellin, O., Patel, R., Duvivier, H., Nassir, Y., Mapes, R., Abaya, C. D., & Swift, R. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1261 · Cited by 43
Encapsulation of α-Particle–Emitting225Ac3+Ions Within Carbon Nanotubes
Matson, M. L., Villa, C. H., Ananta, J. S., Law, J. J., Scheinberg, D. A., & Wilson, L. J. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158311 · Cited by 43
Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate 227Th-rituximab
Dahle, J., Jónasdóttir, T. J., Heyerdahl, H., Nesland, J. M., Borrebæk, J., Hjelmerud, A. K., & Larsen, R. H. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1197-7 · Cited by 42
The Curative and Palliative Potential of the Monoclonal Antibody MOv18 Labelled with211At in Nude Mice with Intraperitoneally growing Ovarian Cancer Xenografts - A Long-Term Study
Håkan Andersson, S. L. (2000) · Acta Oncologica · doi:10.1080/028418600750063820 · Cited by 42
Bystander signaling via oxidative metabolism
Sawal, H. A., Asghar, K., Bureik, M., & Jalal, N. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s136076 · Cited by 40
Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease
Milenic, D. E., Baidoo, K. E., Kim, Y., & Brechbiel, M. W. (2015) · mAbs · doi:10.4161/19420862.2014.985160 · Cited by 39
Alpha Particle Enhanced Blood Brain/Tumor Barrier Permeabilization in Glioblastomas Using Integrin Alpha-v Beta-3–Targeted Liposomes
Sattiraju, A., Xiong, X.-B., Pandya, D. N., Wadas, T. J., Xuan, A., Sun, Y., Jung, Y., Sai, K. K. S., Dorsey, J. F., Li, K. C., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0907 · Cited by 38
Self-citation
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1
Zhang, M., Yao, Z., Patel, H. J., Garmestani, K., Zhang, Z., Talanov, V. S., Plascjak, P. S., Goldman, C. K., Janik, J. E., Brechbiel, M. W., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702496104 · Cited by 37
Integrin Targeted Imaging and Therapy
Chen, X. (2011) · Theranostics · doi:10.7150/thno/v01p0028 · Cited by 37
212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models
Kasten, B. B., Oliver, P. G., Kim, H., Fan, J., Ferrone, S., Zinn, K. R., & Buchsbaum, D. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040925 · Cited by 37
Improvement of Radioimmunotherapy Using Pretargeting
Frampas, É., Rousseau, C., Bodet‐Milin, C., Barbet, J., Chatal, J., & Kraeber‐Bodéré, F. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00159 · Cited by 36
Radioimmunotherapy for Treatment of Acute Leukemia
Bodet‐Milin, C., Kraeber‐Bodéré, F., Eugène, T., Guérard, F., Gaschet, J., Bailly, C., Mougin‐Degraef, M., Bourgeois, M., Faivre-Chauvet, A., Chérel, M., et al. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.10.007 · Cited by 36
Radium and other alpha emitters in prostate cancer
Sartor, O. A., & Sharma, D. (2018) · Translational Andrology and Urology · doi:10.21037/tau.2018.02.07 · Cited by 36
Biodistribution of 211At labeled HER-2 binding affibody molecules in mice
Steffen, A.-C., Almqvist, Y., Chyan, M., Lundqvist, H., Максимилианович, Т. В., Wilbur, D. S., & Carlsson, J. (2007) · Oncology Reports · doi:10.3892/or.17.5.1141 · Cited by 35
One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer
Jadvar, H., CHALLA, S., Quinn, D. I., & Conti, P. S. (2015) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1802 · Cited by 35
177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi
Seidl, C., Zöckler, C., Beck, R., Quintanilla‐Martínez, L., Bruchertseifer, F., & Senekowitsch–Schmidtke, R. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1639-2 · Cited by 35
Nanoconjugation of PSMA-Targeting Ligands Enhances Perinuclear Localization and Improves Efficacy of Delivered Alpha-Particle Emitters against Tumor Endothelial Analogues
Zhu, C., Bandekar, A., Sempkowski, M., Banerjee, S. R., Pomper, M. G., Bruchertseifer, F., Morgenstern, A., & Sofou, S. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0207 · Cited by 35
Fractionated Locoregional Low-Dose Radioimmunotherapy Improves Survival in a Mouse Model of Diffuse-Type Gastric Cancer Using a 213Bi-Conjugated Monoclonal Antibody
Bloechl, S., Beck, R., Seidl, C., Morgenstern, A., Schwaiger, M., & Senekowitsch–Schmidtke, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1004-0017 · Cited by 34
Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy
Gouard, S., Pallardy, A., Gaschet, J., Faivre-Chauvet, A., Bruchertseifer, F., Morgenstern, A., Maurel, C., Matous, E., Kraeber‐Bodéré, F., Davodeau, F., et al. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.02.008 · Cited by 33
Renal Brush Border Enzyme-Cleavable Linkages for Low Renal Radioactivity Levels of Radiolabeled Antibody Fragments
Akizawa, H., Imajima, M., Hanaoka, H., Uehara, T., Satake, S., & Arano, Y. (2013) · Bioconjugate Chemistry · doi:10.1021/bc300428b · Cited by 33
Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a 177 Lu-Labeled Peptide
van Rij, C. M., Frielink, C., Goldenberg, D. M., Sharkey, R. M., Lütje, S., McBride, W. J., Oyen, W. J. G., & Boerman, O. C. (2014) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2014.1660 · Cited by 32
Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific 64Cu-DOTA conjugation
Tavaré, R., Wu, W.-J., Zettlitz, K. A., Salazar, F. B., McCabe, K. E., Marks, J. D., & Wu, A. M. (2014) · Protein Engineering Design and Selection · doi:10.1093/protein/gzu030 · Cited by 32
Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone
Takalkar, A. M., Adams, S., & Subbiah, V. (2014) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-3-23 · Cited by 32
eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer
Shore, N. D., Tutrone, R. F., Jr., Mariados, N. F., Nordquist, L. T., Mehlhaff, B. A., Steere, K. J., & Harrelson, S. S. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.10.022 · Cited by 32
Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma
Li, M., Liu, D., Lee, D., Kapoor, S., Gibson-Corley, K. N., Quinn, T. P., Sagastume, E. A., Mott, S. L., Walsh, S. A., Acevedo, M. R., et al. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00512 · Cited by 32
Description of the Properties of Unattached 218Po and 212Pb Particles by Means of the Classical Theory of Cluster Formation
Raes, F. (1985) · Health Physics · doi:10.1097/00004032-198512000-00013 · Cited by 30
Therapeutic Effect of α-Emitting 224Ra-Labeled Calcium Carbonate Microparticles in Mice with Intraperitoneal Ovarian Cancer
Westrøm, S., Bønsdorff, T. B., Bruland, Ø. S., & Larsen, R. H. (2018) · Translational Oncology · doi:10.1016/j.tranon.2017.12.011 · Cited by 30
223Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice
Dizdarevic, S., Jessop, M., Begley, P., Main, S., & Robinson, A. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4083-3 · Cited by 29
Repeated Intraperitoneal -Radioimmunotherapy of Ovarian Cancer in Mice
Elgqvist, J., Andersson, H., Jensen, H. J., Kahu, H., Lindegren, S., Warnhammar, E., & Hultborn, R. (2009) · Journal of Oncology · doi:10.1155/2010/394913 · Cited by 28
Harmonization of U.S., European Union, and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals: Is This Possible?
Schwarz, S. W., Decristoforo, C., Goodbody, A. E., Singhal, N., Saliba, S., Ruddock, P. S., Zukotynski, K., & Ross, A. A. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.209460 · Cited by 28
Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models By 213Bilabeled Multiple Targeted α Radioimmunoconjugates
Li, Y., Song, E. Y., Rizvi, S. M., Power, C. A., Beretov, J., Raja, C., Cozzi, P. J., Morgenstern, A., Apostolidis, C., Allen, B., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1203 · Cited by 27
In vivo Evaluation of [225Ac]Ac-DOTAZOL for α-Therapy of Bone Metastases
Pfannkuchen, N., Bausbacher, N., Pektor, S., Miederer, M., & Rösch, F. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180604083911 · Cited by 27
Fractionated intravesical radioimmunotherapy with213Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma
Fazel, J., Rötzer, S., Seidl, C., Feuerecker, B., Autenrieth, M. E., Weirich, G., Bruchertseifer, F., Morgenstern, A., & Senekowitsch–Schmidtke, R. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1071735 · Cited by 26
Mechanism of radiation-induced strand break formation in DNA and polynucleotides
Schulte‐Frohlinde, D. (1986) · Advances in Space Research · doi:10.1016/0273-1177(86)90281-4 · Cited by 25
Alpha Particle Emitter Radiolabeled Antibody for Metastatic Cancer: What Can We Learn from Heavy Ion Beam Radiobiology?
Hong, S., Senthamizhchelvan, S., Hobbs, R. F., & Sgouros, G. (2012) · Antibodies · doi:10.3390/antib1020124 · Cited by 25
Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives
van der Doelen, M. J., Mehra, N., Hermsen, R., Janssen, M. J. R., Gerritsen, W. R., & van Oort, I. M. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.11.008 · Cited by 24
The in vivo generator for radioimmunotherapy
Mausner, L. F., Straub, R. F., & Srivastava, S. C. (1989) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.25802601213 · Cited by 23
Structure and properties of DOTA-chelated radiopharmaceuticals within the 225 Ac decay pathway
Khabibullin, A. R., Karolak, A. M., Budzevich, M. M., McLaughlin, M. L., Morse, D. L., & Woods, L. M. (2018) · MedChemComm · doi:10.1039/c8md00170g · Cited by 23
Self-citation
Mutation and Inactivation of Cultured Mammalian Cells Exposed to Beams of Accelerated Heavy Ions
Munson, R. J., Bance, D. A., Stretch, A., & GOODHEAD, D. T. (1979) · International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine · doi:10.1080/09553007914550881 · Cited by 21
The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic
Makvandi, M., Lieberman, B. P., LeGeyt, B. C., Hou, C., Mankoff, D. A., Mach, R. H., & Pryma, D. A. (2015) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2015.10.001 · Cited by 19
Untitled work
(2008) · doi:10.1007/1-4020-3598-5_2 · Cited by 19
Alpha and Proton Heavy Particles and the Bragg Peak in Therapy.
Lawrence, J. H., Tobias, C. A., Born, J. L., Linfoot, J. A., Kling, R., & Gottschalk, A. (1964) · PubMed Central · Cited by 17
Immuno-SPET/CT and immuno-PET/CT: a step ahead to translational imaging
Pecking, A. P., Bellet, D. H., & Alberini, J. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9501-5 · Cited by 16
Recurrent Bleeding in Hemorrhagic Moyamoya Disease : Prognostic Implications of the Perfusion Status
Jo, K.-I., Kim, M. S., Yeon, J. Y., Kim, J. S., & Hong, S. (2016) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2016.59.2.117 · Cited by 16
ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)
Smith, M. R., Parker, C. C., Fred Saad, C., Miller, K., TOMBAL, B. F., Ng, Q. S., Bögemann, M., Matveev, V. B., Piulats, J. M., Zucca, L. E. R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.035 · Cited by 16
Targeted cancer cell ablation in mice by an α-particle-emitting astatine-211-labeled antibody against major histocompatibility complex class I chain-related protein A and B
Li, H. K., Hasegawa, S., Nakajima, N. I., Morokoshi, Y., Minegishi, K., & Nagatsu, K. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.10.157 · Cited by 16
Radioimmunotherapy With Astatine‐211 Using Chimeric Monoclonal Antibody U36 in Head and Neck Squamous Cell Carcinoma
Cheng, J., Ekberg, T., Engström, M., Nestor, M., Jensen, H. J., Максимилианович, Т. В., & Anniko, M. (2007) · The Laryngoscope · doi:10.1097/mlg.0b013e31804b1a6d · Cited by 15
More α Than β for Prostate Cancer?
Fendler, W. P., & Cutler, C. S. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198333 · Cited by 15
Long-lived Alpha Emitters in Radioimmunotherapy: The Mischievous Progeny
Sgouros, G. (2000) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497800414301 · Cited by 13
Exploration of a F(ab′) 2 Fragment as the Targeting Agent of α-Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy
Milenic, D. E., Kim, Y., Baidoo, K. E., Wong, K. J., Barkley, R., Delgado, J. F., & Brechbiel, M. W. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2434 · Cited by 13
Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb
Eriksson, S. E., Bäck, T. A., Elgström, E., Jensen, H. J., Nilsson, R., Lindegren, S., & Tennvall, J. (2013) · EJNMMI Research · doi:10.1186/2191-219x-3-23 · Cited by 12
ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC).
Smith, M. R., Parker, C. C., TOMBAL, B. F., Miller, K., Fred Saad, C., Fang, F., Zhang, A., Kornacker, M., & Higano, C. S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.tps5082 · Cited by 11
Synthesis and metal complexation properties of Ph-DTPA and Ph-TTHA: novel radionuclide chelating agents for use in nuclear medicine
Gouin, S. G., Gestin, J., Monrandeau, L., Dioury, F., Meslin, J. C., & Deniaud, D. (2005) · Organic & Biomolecular Chemistry · doi:10.1039/b413758b · Cited by 10
Role of neuroimaging in drug development
Medhi, B., Misra, S., Avti, P., Kumar, P., Kumar, H., & Singh, B. (2014) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0031 · Cited by 10
Intravesikale Radioimmuntherapie des Carcinoma in situ der Harnblase nach BCG-Versagen
Autenrieth, M. E., Horn, T. D., Kurtz, F., Nguyen, K., Morgenstern, A., Bruchertseifer, F., Schwaiger, M., Blechert, M., Seidl, C., Senekowitsch–Schmidtke, R., et al. (2016) · Der Urologe · doi:10.1007/s00120-016-0273-4 · Cited by 10
Radioimmunotherapy of B-lineage non-Hodgkin's lymphoma using anti-CD19 and anti-CD20 conjugates
Heeger, S., Moldenhauer, G., Flynn, J. M., Egerer, G., Nikula, T. K., Apostolidis, C., Brechbiel, M. W., Haberkorn, U., Ho, A. D., & Haas, R. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.2625 · Cited by 3
Re: 225 Ac-PSMA-617 for PSMA-Targeting Alpha-radiation Therapy of Patients with Metastatic Castration-resistant Prostate Cancer
Hadaschik, B. A. (2016) · European Urology · doi:10.1016/j.eururo.2016.08.028 · Cited by 2
Targeted Alpha Therapy: The US DOE Tri-Lab (ORNL, BNL, LANL) Research Effort to Provide Accelerator-Produced 225 Ac for Radiotherapy
John, K. D. (2017) · APS April Meeting Abstracts · Cited by 2
Innovative Diagnostics Enhances and Advances the Impact of In Vivo Small‐Animal Imaging in Drug Discovery and Pharmaceutical Development
Briel, A. (2013) · doi:10.1002/9783527669417.ch10 · Cited by 1
Molecular Imaging Aided Improvement in Drug Discovery and Development
Chaudhury, S., Thakur, B. L., Chatterjee, S., & Ray, P. (2014) · Current Biotechnology · doi:10.2174/2211550103666140717182415 · Cited by 1

Flagged first, then by citations

17 of the 283 references couldn’t be matched to a known paper.

Research works printed but not linked: 6

Hall, E.J., and Giaccia, A.J. (2006). Radiobiology for the Radiologist, Lippincott Williams & Wilkins.
Hermanson, G.T. (2013). Bioconjugate Techniques, Academic Press. [3rd ed.].
Loevinger, R., Budinger, T.F., and Watson, E.E. (1991). MIRD Primer for Absorbed Dose Calculations, Revised Edition, The Society of Nuclear Medicine, Inc.
Gil, A.V., Pérez, M.C., Aroche, L.T., Pacilio, M., Botta, F., and Cremonesi, M. (2012, January 3–7). MCID: A personalized dosimetric tool associating voxel-based models with MCNP5. Proceedings of the IAEA International Conference on Radiation Protection in Medicine, Setting the Scene for the Next Decade, Bonn, Germany.
Liu, 2001, DOSIMG: A 3D voxel-based Monte Carlo program for absorbed dose calculations, J. Nucl. Med., 42, 243P
Kratochwil, 2015, Ac-225-DOTATOCan empiric dose finding for alpha particle emitter based radionuclide therapy of neuroendocrine tumors, J. Nucl. Med., 56, 1232

Sorted by citations

Antibody–drug conjugates come of age in oncology
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00709-2 · Cited by 903
Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”
Eychenne, R., Chérel, M., Haddad, F., Guérard, F., & Gestin, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060906 · Cited by 210
Ferroptosis in colorectal cancer: Potential mechanisms and effective therapeutic targets
Wang, Y., Zhang, Z., Sun, W., Zhang, J., Xu, Q., Zhou, X., & Mao, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113524 · Cited by 143
Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy
Eychenne, R., Bouvry, C., Bourgeois, M., Loyer, P., Benoist, É., & Lepareur, N. (2020) · Molecules · doi:10.3390/molecules25174012 · Cited by 133
Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives
Hooijman, E. L., Radchenko, V., Ling, S. W., Konijnenberg, M., Brabander, T., Koolen, S. L. W., & de Blois, E. (2024) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-024-00239-1 · Cited by 91

See all 157

Authors: Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., & Morse, D. L.
Affiliations: Moffitt Cancer Center (US)
Wake Forest University Health Sciences (US)
University of South Florida (US)
West Virginia University (US)
Corresponding author: Morse, David L.
ORCID: Tafreshi, Narges K.
Doligalski, Michael L.
Tichacek, Christopher J.
Pandya, Darpan N.
Budzevich, Mikalai M.
El-Haddad, Ghassan
Khushalani, Nikhil I.
Moros, Eduardo G.
McLaughlin, Mark L.
Wadas, Thaddeus J.
Morse, David L.
Venue: Molecules
Publisher: MDPI AG
Published: 2019-11-26
Volume: 24
Issue: 23
Pages: 4314
ISSN: 1420-3049 (ISSN-L)
DOI: 10.3390/molecules24234314
PMC: PMC6930656
OpenAlex: W2990493095
Cited by: 157
References: 283
Citations by year: 2026: 21 · 2025: 25 · 2024: 24 · 2023: 26 · 2022: 23 · 2021: 30 · 2020: 7
FWCI: 2.25
Type: journal article
Language: en
Open access: gold
dx.doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Molecules (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
The Research Repository @ WVU (West Virginia University) (submittedVersion, cc-by)
Funders: Melanoma Research Alliance
National Institutes of Health
National Cancer Institute (P50CA168536)
Topics: Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Physical Sciences › Physics and Astronomy › Radiation › Radioactivity and Radon Measurements
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Chemical Reactions and Isotopes
Keywords: alpha-emitting radionuclides, radiopharmaceuticals, linear energy transfer, tumor targeting, radiation dosimetry, castration-resistant prostate cancer, metastatic prostate cancer, cell death mechanisms, solid tumors
MeSH terms: Alpha Particles, Animals, Antibodies, Monoclonal, Humans, Neoplasms, Radioisotopes, Radiometry, Radiopharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Development of targeted alpha particle therapy for solid tumors.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks